{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-000244","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.042778+00:00","generated_at":"2026-06-07T05:20:12.731140+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"UroGen amends manufacturing pact for UGN-102; extends term to 2027, commits €4.4M for equipment","bullets":["Amendment to manufacturing agreement with Cenexi extends initial term to April 1, 2027.","UroGen revised minimum annual quantity forecasts for bulk mitomycin purchases.","Company agreed to reimburse up to €4.4 million for dedicated capital equipment for UGN-102 production.","Amendment is in anticipation of potential approval and launch of UGN-102, a mitomycin product for low-grade upper tract urothelial cancer.","Parties will negotiate final terms on equipment purchase, installation, and validation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-000244","json":"https://secwatch.observer/filing/0001193125-24-000244.json","markdown":"https://secwatch.observer/filing/0001193125-24-000244.md","text":"https://secwatch.observer/filing/0001193125-24-000244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/0001193125-24-000244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/d231255d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:20:12.731140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a31afb5e43a72c1e0ae0ef5e45151cec4b26bd7","claim":"UroGen Pharma Ltd. amended Amendment No. 2 to Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. valued at approximately €4.4 million (effective 2023-12-28).","evidence_excerpt":"On December 28, 2023, UroGen Pharma Ltd. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to its Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. (“Cenexi”), dated as of April 24, 2020 and amended as of March 2, 2022 (as amended by the Amendment, the “Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/0001193125-24-000244-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Cenexi-Laboratoires Thissen S.A."},{"label":"Value","value":"approximately €4.4 million"},{"label":"Effective","value":"2023-12-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}